Background & Aims In 2017, the World Health Organization (WHO) designated
clarithromycin-resistant Helicobacter pylori a high priority for antibiotic research and …

Background So far, a comprehensive systematic review and meta-analysis has not been
done of the prevalence of primary antibiotic resistance in Helicobacter pylori in the Asia …

Helicobacter pylori (H. pylori) infection is a common worldwide infection that is an important
cause of peptic ulcer disease and gastric cancer. H. pylorimay also have a role in …

Important progress has been made in the management of Helicobacter pylori infection and
in this fifth edition of the Maastricht Consensus Report, key aspects related to the clinical role …

Background We previously showed rising primary antibiotic resistance of Helicobacter pylori
during 1990–2015 in the Asia-Pacific region. However, whether primary antibiotic resistance …

Data are available such that choice of Helicobacter pylori therapy for an individual patient
can be reliably predicted. Here, treatment success is defined as a cure rate of 90% or …

In most regions of the world, antimicrobial resistance has increased to the point where
empirical standard triple therapy for Helicobacter pylori eradication is no longer …

Objective To do a systematic review and meta-analysis of studies comparing sequential
therapy for eradication of Helicobacter pylori with pre-existing and new therapies, thus …

La infección por Helicobacter pylori afecta aproximadamente al 50% de la población
española y es causante de la gastritis crónica, la úlcera péptica y el cáncer gástrico. Se han …

Background The optimal duration for Helicobacter pylori (H. pylori) eradication therapy is
controversial, with recommendations ranging from 7 to 14 days. Several systematic reviews …